Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer
11-Mar-2008 -
Abbott announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) (erlotinib), an oral tablet indicated for the ...
Abbott
acids
chemotherapy
+8